My questions to the board were based on my years o
Post# of 146078
Having said that, I’m not sure if the anti-LL antibodies are being produced in response to the way LL is being packaged as they exit the myocytes or in response to the original introduction to the AAV - but I don’t remember anti-LL antibodies being that much of an issue (if at all) with sub-q LL and that’s why I ponder if adding sub-q LL might add therapeutic benefit.
Thanks for your response, MGK_2. It was helpful.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)